Research
Hormonal
Semaglutide 2.4 mg once weekly is a highly effective treatment for obesity, leading to an average 14.9% body weight loss in nondiabetic adults over 68 weeks, and reduces major adverse cardiovascular events (MACE) in patients with obesity without diabetes.
Semaglutide 2.4 mg once weekly is a powerful treatment for obesity. In clinical trials, it helped people lose nearly 15% of their body weight. It also reduces the risk of major cardiovascular events in people with obesity but no diabetes. Discuss with your doctor if this once-weekly injection is right for you.
StrongSupportsVERY_HIGH confidence
Participants receiving semaglutide lost an average of 14.9% of body weight, compared with 2.4% in the placebo group over 68 weeks. This is also the only RCT in patients with obesity without diabetes that has shown a reduction in major adverse cardiovascular events (MACE) when an intentional weight loss strategy was used [88].
Why this rating
Supported by large-scale, double-blind, randomized controlled studies (STEP 1, SELECT).
Source
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Stefan D. Anker et al. · Journal of Cachexia Sarcopenia and Muscle · 2026
DOI 10.1002/jcsm.70167
clinical_guideline
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Liraglutide 3 mg daily is an effective pharmacological intervention for chronic weight management, producing a mean 5.2 kg placebo-subtracted weight loss at 1 year, with generic availability potentially improving cost-effectiveness in resource-limited settings.Good
- Lifestyle modifications, specifically calorie restriction of 500-750 kcal/day and ≥ 150 minutes of exercise per week, are the first-line treatment for obesity, though long-term maintenance is challenging without pharmacological or surgical support.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →